PTO/SB/08a (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	3

Complete if Known	
Application Number	10/722,587
Filing Date	November 28, 2003
First Named Inventor	ROSENBERG, Robert D.
Art Unit	1623
Examiner Name	Not yet known
Attorney Docket Number	P-6170-US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A	US-2004/0043447	04-03-2004	SARIBAS, et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
						☐
						☐
						☐
						☐
						☐
						☐
						☐
						☐
						☐
						☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

PTO/SB/08b (07-05)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/722,587
				Filing Date	November 28, 2003
				First Named Inventor	ROSENBERG, Robert D.
				Art Unit	1623
(use as many sheets as necessary)				Examiner Name	Not yet known
Sheet	2	of	3	Attorney Docket Number	P-6170-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	B	Aikawa, et al (2001) "Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase. Structure and activity of the fourth member, NDST4." J. Biol. Chem. 276: 5876-82	☐
	C	Habuchi, et al (2000) "The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine." J. Biol. Chem. 275: 2859-68	☐
	D	Kovensky, et al (1999) "A synthetic heparan sulfate pentasaccharide, exclusively containing L-iduronic acid, displays higher affinity for FGF-2 than its D-glucuronic acid-containing isomers." Bioorg. Med. Chem. 7: 1567-80	☐
	E	Kuberan, et al (2002) "Analysis of heparan sulfate oligosaccharides with ion pair-reverse phase capillary high performance liquid chromatography-microelectrospray ionization time-of-flight mass spectrometry." J. Am. Chem. Soc. 124: 8707-18	☐
	F	Leali, et al (2001) "Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives." J. Biol. Chem. 276: 37900-08	☐
	G	Lemieux, et al (1979) "The azidonitration of tri-o-acetyl-D-galactal" Can. J. Chem. 57: 1244-51	☐
	H	Li, et al (1977) "Biosynthesis of Heparin/Heparan Sulfate" J. Biol. Chem. 272(44): 28158-63	☐
	I	Shaklee, et al (1984) "Hydrazinolysis of heparin and other glycosaminoglycans." Biochem. J. 217: 187-97	☐
	J	~~Toshima and Tatsuta (1993) Chem. Rev. 93: 1503-31~~	☐
	K	Orellana, A., et al (1994) "Molecular cloning and expression of a glycosaminoglycan N-acetylglucosaminyl N-deacetylase/N-sulfotransferase from a heparin-producing cell line." *J Biol Chem* **269**, 2270-6	☐
	L	Lloyd, A.G., et al (1971) "Embery, G. & Fowler, L.J. Studies on heparin degradation. I. Preparation of (35 S) sulphamate derivatives for studies on heparin degrading enzymes of mammalian origin." *Biochem Pharmacol* **20**, 637-48	☐
	M	Campbell, P. *et al.* (1994) "Biosynthesis of heparin/heparan sulfate. Purification of the D-glucuronyl C-5 epimerase from bovine liver." *J Biol Chem* **269**, 26953-8	☐

Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./

PTO/SB/08b (07-05)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/722,587
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	November 28, 2003
				First Named Inventor	ROSENBERG, Robert D.
				Art Unit	1623
(use as many sheets as necessary)				Examiner Name	Not yet known
Sheet	3	of	3	Attorney Docket Number	P-6170-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	N	PIKAS, et al (1999) "Enzymes involved in biosynthesis and degradation of heparin-related polysaccharides, Trends in Glycoscience and Glytechnology, vol. 11 no. 61 303-308.	☐
	O	KUSCHE, et al (1991) "Biosynthesis of heparin. Use of Escherichia coli K5 capsular polysaccharide as a model substrate in enzyme polymer-modification reactions, Biochemical Journal vol. 275 no. 1 151-158.	☐
	P	FORSBERG, et al (1999) "Abnormal mast cell in mice deficient in a heparin-synthesizing enzyme, Nature vol. 400 no. 6746 773-776.	☐
	Q	HERNAIZ, et al (*2000) "Enzymatic modifications of heparan sulfate on a biochip promotes its interaction with antithrombin III, BBRC vol. 276 no. 1 292-297.	☐
	R	PEJLER, et al (1987) "Structure and affinity for antithrombin of heraoan sulfate chains derived from basement membrane proteoglycans. J Biol Chem vol 262 no. 1 5036-5043.	☐
	S	Camejo, et al (1992) "Binding of Low Density Lipoproteins by Proteoglycans Synthesized by Proliferating and Quiescent Human Arteial Smooth Muscle Cells." The Journal of Biological Chemistry. 14131-14137.	☐
	T	Galanina, et al (1998) "Determination of Carbohydrate Specificity of Monoclonal Antibodies against MUC1." Tumor Biol. 79-87.	☐
	U	Van den Born, et al (1995) "Presence of N-Unsubstituted Glucosamine Units in Native Heparan Sulfate Revealed by Monoclonal Antibody." The Journal of Biological Chemistry 31303-31309.	☐
	V	Zhou, et al (1997) "Heparin-dependent Fibroblast Growth Factor Activities:Effects of Defined Heparin Oligosaccharides." European Journal of Cell Biology 71-80.	☐
			☐
			☐
			☐

Examiner Signature	/Scarlett Goon/	Date Considered	12/03/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.G./